Literature DB >> 30165127

Patterns of Local-Regional Failure After Intensity Modulated Radiation Therapy or Passive Scattering Proton Therapy With Concurrent Chemotherapy for Non-Small Cell Lung Cancer.

Pei Yang1, Ting Xu2, Daniel R Gomez2, Weiye Deng3, Xiong Wei2, Hesham Elhalawani4, Hekun Jin5, Fada Guan4, Dragan Mirkovic4, Yujin Xu6, Radhe Mohan4, Zhongxing Liao7.   

Abstract

PURPOSE: We compared differences in patterns of locoregional failure, and the influence of adaptive planning on those patterns, in patients who received passive scattering proton therapy (PSPT) versus intensity modulated photon therapy (IMRT) for non-small cell lung cancer. METHODS AND MATERIALS: Treatment simulation computed tomography scans and dose distributions were registered with images depicting the recurrence. Local failure (LF) was defined as failure within the internal target volume (ITV); marginal failure (MF) as failure between the ITV and planning target volume (PTV) plus a 10-mm margin (PTV+10mm); and regional failure (RF) as outside the PTV+10mm. Weekly during-treatment 4-dimensional computed tomography simulation and verification plans were obtained for all patients. Adaptive plans were developed if the verification plan showed deviations in protocol-specified dose distribution, and failure locations were recorded for those patients as well.
RESULTS: Of the 212 patients analyzed, most (152 [72%]) had no failure; of the 60 patients with failure, 27 (45%) had LF (within the ITV), 23 (38%) had MF (between the ITV and PTV+10mm), and 10 (17%) had RF (>10 mm outside the PTV). MF rates were no different for IMRT patients (16 of 136 [12%]) or PSPT patients (7 of 76 [9%], log-rank P = .558). The only independent predictor of MF on Cox proportional hazards analysis was T3-4 status. Large tumors and use of PSPT independently predicted the need for adaptive planning. Although 5-year overall survival rates were poorer for patients with large tumors versus small tumors (P < .001), the rates were similar for patients with large tumors who received adaptive planning versus small tumors.
CONCLUSIONS: No differences in LF, MF, or RF patterns were found for IMRT versus PSPT. Proton therapy more often required adaptive planning, and the techniques used for adaptive planning did not compromise tumor control. Response to chemoradiation by larger tumors predicted favorable survival.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2018        PMID: 30165127     DOI: 10.1016/j.ijrobp.2018.08.031

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

Review 1.  Proton therapy for locally advanced non-small cell lung cancer.

Authors:  Olsi Gjyshi; Zhongxing Liao
Journal:  Br J Radiol       Date:  2019-08-20       Impact factor: 3.039

2.  A Review of Proton Therapy - Current Status and Future Directions.

Authors:  Radhe Mohan
Journal:  Precis Radiat Oncol       Date:  2022-04-27

3.  Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience.

Authors:  Nathan Y Yu; Todd A DeWees; Chenbin Liu; Thomas B Daniels; Jonathan B Ashman; Staci E Beamer; Dawn E Jaroszewski; Helen J Ross; Harshita R Paripati; Jean-Claude M Rwigema; Julia X Ding; Jie Shan; Wei Liu; Steven E Schild; Terence T Sio
Journal:  Adv Radiat Oncol       Date:  2019-08-21

Review 4.  Is there any benefit to particles over photon radiotherapy?

Authors:  Maria E Goossens; Marc Van den Bulcke; Thierry Gevaert; Lydie Meheus; Dirk Verellen; Jean-Marc Cosset; Guy Storme
Journal:  Ecancermedicalscience       Date:  2019-12-09

5.  Anatomic change over the course of treatment for non-small cell lung cancer patients and its impact on intensity-modulated radiation therapy and passive-scattering proton therapy deliveries.

Authors:  Mei Chen; Jinzhong Yang; Zhongxing Liao; Jiayi Chen; Cheng Xu; Xiaodong He; Xiaodong Zhang; Ronald X Zhu; Heng Li
Journal:  Radiat Oncol       Date:  2020-03-05       Impact factor: 3.481

Review 6.  Adaptive Radiation Therapy in the Treatment of Lung Cancer: An Overview of the Current State of the Field.

Authors:  Huzaifa Piperdi; Daniella Portal; Shane S Neibart; Ning J Yue; Salma K Jabbour; Meral Reyhan
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244

Review 7.  Imaging Strategies in Proton Therapy for Thoracic Tumors: A Mini Review.

Authors:  Carlo Algranati; Lidia Strigari
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

Review 8.  Roadmap: proton therapy physics and biology.

Authors:  Harald Paganetti; Chris Beltran; Stefan Both; Lei Dong; Jacob Flanz; Keith Furutani; Clemens Grassberger; David R Grosshans; Antje-Christin Knopf; Johannes A Langendijk; Hakan Nystrom; Katia Parodi; Bas W Raaymakers; Christian Richter; Gabriel O Sawakuchi; Marco Schippers; Simona F Shaitelman; B K Kevin Teo; Jan Unkelbach; Patrick Wohlfahrt; Tony Lomax
Journal:  Phys Med Biol       Date:  2021-02-26       Impact factor: 4.174

9.  Substantial Sparing of Organs at Risk with Modern Proton Therapy in Lung Cancer, but Altered Breathing Patterns Can Jeopardize Target Coverage.

Authors:  Camilla Grindeland Boer; Kristine Fjellanger; Inger Marie Sandvik; Maren Ugland; Grete May Engeseth; Liv Bolstad Hysing
Journal:  Cancers (Basel)       Date:  2022-03-08       Impact factor: 6.639

10.  AAPM Task Group Report 290: Respiratory motion management for particle therapy.

Authors:  Heng Li; Lei Dong; Christoph Bert; Joe Chang; Stella Flampouri; Kyung-Wook Jee; Liyong Lin; Michael Moyers; Shinichiro Mori; Joerg Rottmann; Erik Tryggestad; Sastry Vedam
Journal:  Med Phys       Date:  2022-01-31       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.